Cannabis Law Report

AUGUST 22, 2021

Silo Pharma’s notice of allowance paves the way toward clinical trials for its psychedelics delivery platform using homing peptides. Unlike competitors administering generic psychedelics, the company’s patented technology could improve safety and efficacy while guaranteeing market exclusivity. Silo Pharma Inc. Silo Pharma Inc.

Clinical Trials 105

Clinical Trials Research and Development Safety Treatment 105

Cannabis Law Report

JUNE 10, 2021

The Traffic Safety Culture Index is an annual survey with national scope and multiple measures relevant to driving after marijuana use. Because THC presence is an imperfect proxy for impairment [ 10 ], driving data may be limited in clarifying what traffic safety risks, if any, are associated with permissive marijuana policies.

Policy 59

Policy Safety Marijuana Data 59

Cannabis Law Report

DECEMBER 9, 2021

The Financing will allow the Company to continue progressing its R&D, clinical trials and technology initiatives. “I I’m proud of our accomplishments to date and look forward to kicking off multiple clinical trials in early 2022,” said CEO, Josh Bartch. DENVER, Dec. launched their app platform Mindleap 2.0

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Cannabis Law Report

NOVEMBER 24, 2019

Do not offer CBD to manage chronic pain in adults unless as part of a clinical trial. the person’s clinical condition is stable. There is limited evidence on the safety of cannabis-based medicinal products during pregnancy and breastfeeding. Tools and resources. Recommendations. Recommendations for research.

Medicine 59

Medicine Chronic Pain Research and Development Treatment 59

TheAnswerPage

JANUARY 11, 2022

We also provide free downloadable resources: ‘The Endocannabinoid System and Medical Marijuana in 15 minutes!’ We provide free educational resources, including ‘The Answer of the Day,’ a daily question and answer email that reviews the medical marijuana articles published in the peer-reviewed medical journals.

Patients 98

Patients Education Marijuana Therapy 98

Project CBD

FEBRUARY 28, 2023

Despite the companies’ submitting the required data demonstrating the “reasonable expectation of safety under the recommended conditions of use,” the FDA rejected the applications, citing the drug preclusion clause. Available at: www.fda.gov/media/131878/download. US Food and Drug Administration website. Accessed October 17, 2022.

CBD 144

CBD Seed-To-Sale Food Access 144

CannaMD

MARCH 8, 2021

Download CannaMD ‘s official opposition memo , outlining court precedents, research highlights, and more details regarding the Federal Communications Commission and U.S. Authorizing the department to sample marijuana delivery devices from a dispensing facility to determine safety [p. 1, line 14]. 1, line 17]. 1, line 19].

THC 116

THC Research and Development Treatment Patients 116